AN ACT to amend Tennessee Code Annotated, Title 8; Title 41; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to the use of drugs for the treatment of pain.
Impact
The enactment of SB1790 is expected to influence state laws regarding pharmaceutical coverage within health insurance policies. By mandating that non-opioid medications are not disadvantaged on insurers’ preferred drug lists, the bill aims to mitigate the opioid crisis by encouraging the adoption of safer pain management alternatives. It applies specifically to medications that have received approval from the United States Food and Drug Administration and are on the market for a designated period, reinforcing a structured approach to drug policy in the state.
Summary
Senate Bill 1790 is an initiative aimed at amending various sections of the Tennessee Code Annotated related to the use of drugs for pain treatment. Central to the bill is the promotion of non-opioid medications in the pain management context. This legislation seeks to ensure that non-opioid options are presented equitably alongside opioid medications within insurance coverage guidelines. Specifically, insurers are required to maintain a Preferred Drug List (PDL) that does not discourage the coverage of non-opioids relative to opioids, thereby fostering a more diverse approach to pain treatment.
Contention
Notable discussions surrounding SB1790 have included varying perspectives on the scope of its implementation. Proponents argue that the bill is a necessary step toward reducing reliance on opioid prescriptions, thus addressing a pressing public health issue. However, there have been concerns regarding the practicality of enforcement and whether the changes will significantly alter prescribing habits among healthcare providers. Critics may also argue about the adequacy of non-opioid options for certain patients, suggesting that not all pain conditions are suitably addressed without opioid medications.
Implementation
Should SB1790 pass, its stipulations will take effect on January 1, 2027. The timeline provides a window for healthcare insurers and providers to adapt to the new requirements, potentially necessitating changes in prescribing practices and insurance policies regarding pain management treatments. As such, the bill is positioned as a forward-thinking measure to recalibrate pain treatment approaches and foster better health outcomes.
Crossfiled
AN ACT to amend Tennessee Code Annotated, Title 8; Title 41; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to the use of drugs for the treatment of pain.
AN ACT to amend Tennessee Code Annotated, Title 8; Title 41; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to the use of drugs for the treatment of pain.
AN ACT to amend Tennessee Code Annotated, Title 8; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to the use of drugs for the treatment of pain.
AN ACT to amend Tennessee Code Annotated, Title 8; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to the use of drugs for the treatment of pain.
AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.